Evaxion is a biotechnology company that specializes in developing immunotherapies and vaccines using advanced computational methods. The company focuses on leveraging artificial intelligence and machine learning to design and optimize treatments for various diseases, particularly cancers and infectious diseases. By utilizing in silico techniques, Evaxion aims to accelerate the discovery and development of effective therapeutic solutions, thereby enhancing the understanding of immune responses and improving patient outcomes in immunotherapy.
Evaxion Trajectory Shift Evaxion Biotech (NASDAQ: EVAX) has just implemented a significant change to its American Depositary Shares (ADS) ratio, set in motion from January 14, 2025. Previously, each ADS…